Key Quantitative Figures

  • OTS Settlement Profit: ₹606.23 crore recognized under exceptional items in Q2FY2025-26
  • Trade Receivables: ₹1,69,921.85 lakhs outstanding for more than 3 years
  • Provision for Doubtful Debts: ₹62,727.62 lakhs provided, with additional ₹1,07,194.23 lakhs considered "Having Significant increase in credit risk"
  • Property Values:
  • Jawahar Vyapar Bhawan: ₹55,929 lakhs
  • Housing Colony at Aurobindo Marg: ₹12,394 lakhs
  • Asian Games Village Flats: ₹2,720 lakhs
  • Mumbai apartments: ₹1,918 lakhs
  • Statutory Dues:
  • GST input non-claimable: ₹54.91 lakhs
  • TDS default: ₹11.22 lakhs
  • L&DO Demand: ₹13,283 lakhs for period March 2004-July 2018, with ₹4,743 lakhs not provided
  • Penalties: Cumulative fines of approximately ₹148.73 lakhs imposed by BSE and NSE

Dates of Action

  • Board Meeting: August 25, 2026 (2:30 PM to 6:30 PM)
  • OTS Completion: July 11, 2025 (Settlement Certificate issued)
  • DRT Case Withdrawal: July 15, 2025
  • MBPT Surrender Certificate: November 12, 2021
  • DRAT Pre-deposit: May 20, 2026 (₹10.62 crore deposited)
  • Next Hearing Date: October 23, 2026 (DRAT appeal)

Parties Involved

  • Auditors: P V A R & Associates, Chartered Accountants
  • Lender Banks: Canara Bank (lead banker), five other lender banks
  • Regulators: SEBI, BSE, NSE, Ministry of Corporate Affairs, CAG
  • Subsidiary: STCL Limited
  • Legal Counterparties: M/s Rajat Pharmaceuticals Ltd., foreign buyers (Loben Trading Co. Pte. Ltd., Singapore; Sweetland Trading Pte Ltd., Singapore)
  • Property Authorities: L&DO, DMRC, MBPT, NDMC

Purpose/Rationale

The results disclosure is a regulatory requirement under SEBI LODR Regulations. The company has prepared accounts on a "non-going concern basis" following ministry directives since FY2021-22. The OTS was undertaken to settle outstanding debts with lender banks.

Financial Impact

Confirmed Impacts:

  • Profit increased by ₹606.23 crore due to OTS settlement
  • Non-current assets potentially overstated by ₹26.51 lakhs (₹11.67 lakhs + ₹14.84 lakhs) for MBPT properties
  • Trade receivables potentially overstated by ₹1,07,194.23 lakhs due to inadequate provisioning
  • Other current assets potentially overstated by ₹3,192.14 lakhs
  • Liabilities potentially understated by ₹4,743 lakhs for L&DO demands

Contingent Exposures:

  • Potential liability of ₹2,655 lakhs in ICICI Bank vs. STC & Ors case (₹1,062 lakhs pre-deposited with DRAT)
  • Claims of ₹47,647 lakhs from banks/financial institutions against RPL making STC a party
  • Cumulative penalties of ₹148.73 lakhs by stock exchanges (waiver applications pending)
  • Interest accumulation on L&DO dues estimated at ₹102.48 crore (from July 2018 to March 2026)

Capital Structure Impact

No change in equity share capital remains at ₹6,000 lakhs. Other equity shows negative balance of ₹(33,164.14) lakhs (standalone) and ₹(4,88,936.16) lakhs (consolidated).

Cash Flow Implications

  • OTS payment of ₹200 crore made to lender banks
  • DRAT pre-deposit of ₹10.62 crore made
  • Operating cash flow showed net increase of ₹616.771 lakhs in FY2025-26

Governance Issues

  • No full-time working directors as of March 31, 2026
  • Board-level committees not reconstituted due to non-appointment of independent directors since November 2024
  • Subsidiary STCL Limited's financial statements not approved by its board
  • Internal financial controls show qualified opinion with material weaknesses

Audit Opinion

Standalone: Qualified opinion with multiple basis for qualifications including property title issues, trade receivables valuation, foreign currency revaluation, statutory dues reconciliation, and investments valuation.

Consolidated: Disclaimer of opinion due to significance of qualifications in standalone financials and limitation of scope regarding unapproved/unaudited financial statements of subsidiary STCL Limited.

Additional Information

  • The company is functioning with only independent directors and director (finance) on additional charge
  • Financial statements prepared on non-going concern basis as per ministry directives
  • 272 criminal complaints filed u/s 138 of N.I. Act in the Rajat Pharmaceuticals matter
  • CBI investigation ongoing in certain matters
  • New labor codes may have financial implications from FY2026-27 onward